glp-1 news 2025 november Agonists Weight Loss Drugs Market Report, 2025-2030 Wegovy maker Novo Nordisk makes

J Pain (2017) 18(4):359.e1359.e38

Compounded versions of semaglutide existed (and were heavily marketed through telehealth platforms), but the FDA is cracking down on compounders making GLP-1 products now that the drug shortage has ended

Drug interactions are possible with prescription pain medications and other medications

They minimize systemic inflammation by many mechanisms: direct suppression of pro-inflammatory cytokine synthesis (TNF-, IL-6, IL-1), augmentation of anti-inflammatory mediators (IL-10, adiponectin), and alteration of immune cell morphologies

Around 30-50% of users experience side effects during the first few weeks of therapy as appetite, digestion, and metabolism begin to change